

# Key Juven® Study Summaries

CITATION	STUDY DESIGN	PATIENT POPULATION	GROUPS	OUTCOMES
Williams JZ et al. <i>Ann Surg.</i> 2002;236:369-74.	RCT	Healthy elderly 70+ years N=35	<ul style="list-style-type: none"> <li>Juven</li> <li>Isonitrogenous, isocaloric placebo</li> </ul>	<b>Significant increase in wound collagen deposition</b> as reflected by hydroxyproline content in the Juven group as compared to the placebo control group (p<0.03).
Tatti P & Barber AE. <i>EWMA J</i> 2010;10(3):13-17.	Retrospective analysis	Patients with recurring diabetic foot ulcers N=12	<ul style="list-style-type: none"> <li>Juven</li> <li>Historical control</li> </ul>	<b>Time to wound closure was significantly decreased</b> in patients receiving Juven (p<0.05).
Sipahi S et al. <i>BMC Nephrol.</i> 2013; 14(8): 1-6.	Retrospective analysis	Patients with diabetic ulcers and chronic renal failure and on hemodialysis N=11	<ul style="list-style-type: none"> <li>Juven</li> </ul>	<b>Wound appearance (p=0.001) and wound depth scores (p=0.006) significantly improved</b> after 4 weeks of Juven.
Jones MS, et al. <i>Surgical Infections,</i> 2014; 15(6):708-712.	RCT	Patients undergoing wound debridement for diabetic foot ulcers N=9	<ul style="list-style-type: none"> <li>Juven</li> <li>Placebo</li> </ul>	<b>Significant increase in hydroxyproline</b> concentration in Juven group compared to placebo group (p=0.03).
Armstrong DG et al. <i>Diabet Med.</i> 2014 September; 31(9): 1069–1077.	RCT	Patients with diabetic foot ulcers N=270	<ul style="list-style-type: none"> <li>Juven</li> <li>Placebo control</li> </ul>	<p><b>Significantly greater proportion of subjects with total wound closure at 16 weeks in the Juven group compared to the control group in patients at risk of poor limb perfusion (p=0.0079).</b></p> <p><b>Juven increased likelihood ulcer would heal by 70% relative to placebo in patients at risk for malnutrition (p=0.0325).</b></p>
Wong A et al. <i>J Wound Care</i> 2014;23(5):259-269.	RCT	Patients with pressure ulcers N=23	<ul style="list-style-type: none"> <li>Juven + ONS</li> <li>ONS</li> </ul>	<p><b>Significant increase in proportion of viable tissue</b> in Juven + ONS vs. ONS group (p=0.02).</p> <p><b>Improvement in PUSH scores after 1 week</b> in Juven + ONS vs. ONS group (p=0.013).</p>
Imai T et al. <i>Jpn J Clin Oncol</i> 2014; 44(5):422-427.	RCT	Patients with head and neck cancer N=40	<ul style="list-style-type: none"> <li>Juven</li> <li>Control (no supplement)</li> </ul>	<p><b>Incidence of Grade 2 or greater dermatitis</b> was significantly (p&lt;0.05) lower in patients receiving Juven compared to control.</p> <p><b>Duration of Grade 1 or greater dermatitis</b> was significantly shorter in patients receiving Juven (p&lt;0.01).</p>
Sari SY et al. <i>Clin Nutr ESPEN.</i> 2016; 16:30-35.	Prospective Matched	Patients with head and neck cancer treated with radiotherapy N=29	<ul style="list-style-type: none"> <li>Juven</li> <li>Control (no supplement)</li> </ul>	<b>Cancer patients receiving radiotherapy and Juven had better quality of life scores</b> as compared to those not receiving Juven (ps<0.05).

# Key Juven® Study Summaries

CITATION	STUDY DESIGN	PATIENT POPULATION	GROUPS	OUTCOMES
Clark RH et al. <i>JPEN</i> 2000; 24: 133-139.	RCT	Patients with AIDS associated wasting N=43	<ul style="list-style-type: none"> <li>Juven</li> <li>Placebo</li> </ul>	<b>Significant increase in lean body mass</b> in the Juven group as compared to the placebo control group (p<0.003).
May PE et al. <i>Am J Surgery</i> 2002; 183:471-479.	RCT	Patients with cancer associated wasting N=32	<ul style="list-style-type: none"> <li>Juven</li> <li>Placebo</li> </ul>	<b>Significant increase in lean body mass</b> in the Juven group as compared to the placebo control group (p<0.02).
Nishizaki K et al. <i>Asia Pac J Clin Nutr</i> 2015; 24:412-420.	RCT	Osteoarthritis patients who underwent total knee arthroplasty N=23	<ul style="list-style-type: none"> <li>Juven</li> <li>Control</li> </ul>	<b>Suppressed the loss of muscle strength after total knee arthroplasty.</b>
Ellis A et al. <i>Eur J Clin Nutr</i> 2016; 70:269-273.	RCT	Elderly community-dwelling N=31	<ul style="list-style-type: none"> <li>Juven</li> <li>Placebo</li> </ul>	<b>Significantly improved vascular endothelial function</b> (increase in flow-mediated dilation) p=0.003.